Oncolytics Biotech Inc (ONCY) SEC Filing 6-K Foreign Issuer Report for the period ending Monday, August 14, 2023

Oncolytics Biotech Inc

CIK: 1129928 Ticker: ONCY

View differences made from one to another to evaluate Oncolytics Biotech Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncolytics Biotech Inc.


Assess how Oncolytics Biotech Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncolytics Biotech Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Oncolytics Biotech Inc provided additional information to their SEC Filing as exhibits

Ticker: ONCY
CIK: 1129928
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001129928-23-000046
Submitted to the SEC: Mon Aug 14 2023 8:41:18 AM EST
Accepted by the SEC: Mon Aug 14 2023
Period: Monday, August 14, 2023
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: